RGD Reference Report - Immunotherapy of alveolar echinococcosis via PD-1/PD-L1 immune checkpoint blockade in mice. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Immunotherapy of alveolar echinococcosis via PD-1/PD-L1 immune checkpoint blockade in mice.

Authors: Wang, Junhua  Jebbawi, Fadi  Bellanger, Anne-Pauline  Beldi, Guido  Millon, Laurence  Gottstein, Bruno 
Citation: Wang J, etal., Parasite Immunol. 2018 Dec;40(12):e12596. doi: 10.1111/pim.12596. Epub 2018 Nov 4.
RGD ID: 41410787
Pubmed: PMID:30315719   (View Abstract at PubMed)
PMCID: PMC6587932   (View Article at PubMed Central)
DOI: DOI:10.1111/pim.12596   (Journal Full-text)

The growth potential of the tumour-like Echinococcus multilocularis metacestode (causing alveolar echinococcosis, AE) is directly dependent upon the nature/function of the periparasitic adaptive host immune-mediated processes. PD-1/PD-L1 pathway (programmed cell death 1), which inhibits lymphocytic proliferation in tumour development, is over-expressed at the chronic stage of AE. We tested the impact of a PD-1/PD-L1 pathway blockade on the outcome of both chronic AE (intraperitoneal metacestode inoculation, secondary AE and SAE) and acute AE (peroral egg infection, primary AE and PAE). To assess the parasite proliferation potential, we measured parasite mass weight for SAE and liver lesion number for PAE. In both models, the parasite load was significantly decreased in response to anti-PD-L1 antibody treatment. In SAE, anti-PDL1 administration was associated with increased Th1 response parameters and decreased Treg responses, while in PAE anti-PDL1 administration was associated with fewer lesions in the liver and decreased Treg/Th2 responses. Our findings highly suggested that a PD-1/PD-L1 pathway blockade triggered the host immune responses in favour of an immune-mediated control of E. multilocularis proliferation. Based on this, future studies that combine PD-1/PD-L1 blockade with a parasitostatic albendazole medication may yield in a putatively curative therapeutic approach to control alveolar echinococcosis.



RGD Manual Disease Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
CD274Humanalveolar echinococcosis treatmentISOCd274 (Mus musculus) RGD 
Cd274Mousealveolar echinococcosis treatmentIMP  RGD 
Cd274Ratalveolar echinococcosis treatmentISOCd274 (Mus musculus) RGD 

Objects Annotated

Genes (Rattus norvegicus)
Cd274  (CD274 molecule)

Genes (Mus musculus)
Cd274  (CD274 antigen)

Genes (Homo sapiens)
CD274  (CD274 molecule)


Additional Information